Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03699319
Previous Study | Return to List | Next Study

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03699319
Recruitment Status : Recruiting
First Posted : October 9, 2018
Last Update Posted : January 8, 2021
Sponsor:
Information provided by (Responsible Party):
Jeffrey Hardacre, Case Comprehensive Cancer Center

Brief Summary:
The purpose of this study is to treat participants with the combination of CPI-613 (the study drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and effective for participants with localized and unresectable pancreatic cancer. This study is specifically for participants who have a pancreatic cancer that is localized and not considered resectable or removable by a surgeon, without additional treatment.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: CPI 613 Drug: Oxaliplatin Drug: Irinotecan Drug: 5-flurouracil Drug: Folinic acid Phase 1 Phase 2

Detailed Description:

This is a single-arm study of participants with locally advanced pancreatic ductal adenocarcinoma evaluating combination CPI-613 with modified FOLFIRINOX, with the addition of a dose escalation cohort to assess safety. All study participants will get the same study intervention, which includes the best available treatment for locally advanced pancreatic cancer, plus an experimental therapy. The standard therapy is called mFOLFIRINOX, which is a combination of three chemotherapy drugs (Oxaliplatin, Irniotecan and 5-flurouracil) and one additional vitamin derivative (Folinic acid). The experimental drug is CPI-613, which inhibits energy production in cells, and early studies suggest that pancreatic cancer cells may be especially sensitive. Pre-treatment, diagnostic biopsy tissue will be collected when available, and clinical data will be evaluated to determine if the combination results in improved overall survival compared to historical experience. Based on new data, the study team will also attempt to identify a new maximum tolerated dose (MTD) of CPI-613 in a phase 1 open-label dose-regimen finding study.

The objectives of the Standard Dose Cohort are to determine the safety and efficacy of CPI-613, in combination with mFOLFIRINOX for locally advanced pancreatic cancer.

The objectives of the Dose Escalation Cohort is to determine a new maximum-tolerated dose (MTD) of CPI-613 when given in combination with mFOLFIRINOX.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single-armed study of patients with locally advanced pancreatic cancer, evaluating combination CPI-613 with modified FOLFIRINOX
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II/I Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status
Actual Study Start Date : December 4, 2018
Estimated Primary Completion Date : May 1, 2021
Estimated Study Completion Date : May 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Standard Dose Cohort: CPI-613 + mFOLFIRINOX

Novel drug and mitochondrial inhibitor, CPI-613 in conjunction with standard-of-care FOLFRINOX.

Consists of a Standard Dose Cohort and Dose escalation cohort using a standard 3 + 3 design starting at 750 mg/m^2 given at a rate of 4 ml/min ("dose level (DL) 2"). Participants receiving a dose of 1000mg/m^2 will be treated over 2 hours. In the absence of any DLT, the next DL will begin enrollment. If 1 DLT occurs, the DL will be expanded by 3 participants. If <33% of participants experience a DLT, the next DL will be opened and will proceed in similarly. Only 2 DLs are expected to be studied: 750 mg/m^2 and 1000 mg/m^2.

Participants may be enrolled in this cohort after the accrual goal of the standard cohort is met but prior to the completion of treatment of all patients in the standard dose cohort

Participants experiencing a DLT will be allowed to continue on the study at the standard DL of 500 mg or lower.

Drug: CPI 613

Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.

Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.

Intended treatment protocol is 12 cycles (2 weeks each) or 6 months

Other Name: 6, 8-bis-benzylsulfanyloctanoic acid

Drug: Oxaliplatin

Administered at 65 mg/m2 given as a 2-hr IV

Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)

Other Name: Eloxatin

Drug: Irinotecan

Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector

Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)

Other Name: Camptosar

Drug: 5-flurouracil

Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan

Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)

Other Name: 5FU

Drug: Folinic acid

Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin

Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)

Other Names:
  • Leucovorin
  • Calcium folinate
  • FA




Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Three years after start of study ]

    Interval between enrollment and death for participants for all participants.

    Median OS will be estimated using the Kaplan-Meier method along with a two-sided 80% confidence interval (CI). OS will be documented and reported separately per cohort


  2. MTD of CPI-613 when given in combination with mFOLFIRINOX [ Time Frame: Up to 4 weeks from start of treatment ]
    MTD of CPI-613 when given in combination with mFOLFIRINOX in the added small cohort of participants with higher doses of CPI-613 developed to redefine MTD


Secondary Outcome Measures :
  1. Median Progression free survival (PFS) [ Time Frame: Three years after start of study ]

    Median (and 95% CI) time from study enrollment to progression or death from any cause for all participants.

    Distribution of PFS will be estimated using the Kaplan-Meier method. Participants alive at the end of follow-up are censored. PFS will be documented and reported separately per cohort


  2. Median Time to progression (TTP) [ Time Frame: Three years after start of study ]

    Median (and 95% CI) time from enrollment to progression

    Distribution of TTP will be estimated using the Kaplan-Meier method. Participants who die but have not progressed are censored.


  3. Response rates per RECIST version 1.1 [ Time Frame: Three years after start of study ]
    RECIST version 1.1 response rates including complete response, partial response and stable disease (CR+PR+SD).

  4. Complete pathologic response rates (CRp) [ Time Frame: Three years after start of study ]

    CRp defined as the proportion of participants that are designated having a complete response after treatment on protocol, evidenced by tissue samples taken during the subsequent resection

    CRp is defined by the NCI as "the lack of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with radiation or chemotherapy".


  5. Resection margins [ Time Frame: Three years after start of study ]

    Resection margins are defined by the NCI as "The edge or border of the tissue removed in cancer surgery. The margin is described as negative or clean when the pathologist finds no cancer cells at the edge of the tissue, suggesting that all of the cancer has been removed. The margin is described as positive or involved when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed."

    The rate of negative resection margins will be estimates with 95 % confidence intervals


  6. Surgical resection rates [ Time Frame: Up to 4 weeks from end of treatment ]
    Percent of participants previously determined to be borderline- or non-resectable that undergo complete surgical resection after treatment on protocol.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed pancreatic adenocarcinoma.
  • Participants must have locally advanced (including unresectable or borderline resectable) pancreatic cancer based on CT or MRI imaging (pancreas protocol CT of the abdomen and pelvis if possible, MRI with contrast or CT with oral and IV contrast in the absence of a pancreas protocol CT scan, CT of the chest with or without contrast) as determined by the PI or Co-investigators. Participants with contrast allergies may be permitted without contrast scans if approved by the PI or Co-Investigators for safety reasons.
  • Eastern Cooperative Oncology Group (ECOG) Performance status being 01 within 1 week of planned start of therapy.
  • Participants must have normal organ and marrow function as defined below < 2 weeks must be:

    • Adequate hematologic (white blood cell [WBC] >= 3500 cells/mm3; platelet count >= 100,000 cells/mm3; absolute neutrophil count [ANC] >=1500 cells/mm3; and hemoglobin >=8 g/dL).
    • Adequate hepatic function (aspartate aminotransferase [AST/SGOT] 3x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] <=3x UNL, bilirubin <=1.5x UNL).
    • Adequate renal function (serum creatinine <=2.0 mg/dL or 177 µmol/L).
    • Adequate coagulation ("International Normalized Ratio" or INR must be <1.5) unless on therapeutic blood thinners.
  • Expected survival >=3 months in the view of the PI or investigators.
  • Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.
  • Fertile men must practice effective contraceptive methods (i.e. surgical sterilization, or a condom used with a spermicide) during the study, unless documentation of infertility exists.
  • No evidence of clinically significant active infection and no serious infection within the past month requiring hospitalization.
  • Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants with endocrine or acinar pancreatic carcinoma.
  • Participants with resectable pancreatic cancer.
  • Participants with metastatic pancreatic cancer based on imaging.
  • Participants who have received prior surgical or medical treatment for pancreatic cancer.
  • Participants receiving any other standard or investigational treatment for their cancer with a primary goal of improving survival within the past 2 weeks prior to initiation of CPI-613 treatment.
  • Pregnant women or breast feeding women, or women of child-bearing potential not using reliable means of contraception are excluded from this study because the teratogenic or abortifacient effects of CPI-613 is unknown. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CPI-613, breastfeeding should be discontinued if the mother is treated with CPI-613. These potential risks may also apply to other agents used in this study.
  • Fertile men unwilling to practice contraceptive methods during the study period.
  • Participants with a life expectancy less than 3 months.
  • Participants with a serious medical illness that would potentially increase participants' risk for toxicity
  • Participants with any active uncontrolled bleeding, and any participnats with a bleeding diathesis (e.g., active peptic ulcer disease).
  • Participants with a history of myocardial infarction that is <3 months prior to registration.
  • Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure or coronary artery disease, unstable angina pectoris, cardiac arrhythmia, symptomatic myocardial infarction or psychiatric illness/social situations that would limit compliance with study requirements.
  • Participants who are known to be HIV-positive and on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with CPI-613.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03699319


Contacts
Layout table for location contacts
Contact: Erin Anderson, RN 1-800-641-2422 erin.anderson@uhhospitals.org

Locations
Layout table for location information
United States, Ohio
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Jeffrey Hardacre, MD    800-641-2422    CTUReferral@uhhospitals.org   
Sponsors and Collaborators
Jeffrey Hardacre
Investigators
Layout table for investigator information
Principal Investigator: Jeffery Hardacre, MD University Hospitals Cleveland Medical Center
Layout table for additonal information
Responsible Party: Jeffrey Hardacre, MD, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT03699319    
Other Study ID Numbers: CASE2218
First Posted: October 9, 2018    Key Record Dates
Last Update Posted: January 8, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jeffrey Hardacre, Case Comprehensive Cancer Center:
FOLFIRINOX
CPI-613
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Leucovorin
Folic Acid
Oxaliplatin
Irinotecan
Levoleucovorin
Physiological Effects of Drugs
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antidotes
Protective Agents
Vitamin B Complex
Vitamins
Micronutrients
Nutrients
Growth Substances
Hematinics